drugset / Trial / NCT00572455
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the safety and efficacy of PF-04217329.
Timeline
- Start
- 2007-12-11
- Primary completion
- 2009-06-26
- Completion
- 2009-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Latanoprost | Small molecule | 0.005 % | Topical |
| Subject | taprenepag isopropyl | Small molecule | 0.0025 % | Topical |
| Subject | taprenepag isopropyl | Small molecule | 0.005 % | Topical |
| Subject | taprenepag isopropyl | Small molecule | 0.01 % | Topical |
| Subject | taprenepag isopropyl | Small molecule | 0.015 % | Topical |
| Subject | taprenepag isopropyl | Small molecule | 0.02 % | Topical |
| Subject | taprenepag isopropyl | Small molecule | 0.03 % | Topical |